Case report: Severe combined immunodeficiency with ligase 1 deficiency and Omenn-like manifestation.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 31 08 2022
accepted: 03 10 2022
entrez: 7 11 2022
pubmed: 8 11 2022
medline: 9 11 2022
Statut: epublish

Résumé

DNA ligase I deficiency is an extremely rare primary immunodeficiency with only 6 patients reported in the literature. Most common manifestations include radiosensitivity, macrocytic anemia, lymphopenia with an increased percentage of gamma-delta T cells, and hypogammaglobulinemia requiring replacement therapy. Two-month-old girl with delayed development, T-B-NK+ SCID, and macrocytic anemia presented features of Omenn syndrome. Whole exome sequencing revealed two novel, heterozygous variants (c.2312 G>A, p.Arg771Gly and c.776+5G>T, p.Pro260*) in the LIG1 gene (NM_000234.1). Hematopoietic stem cell transplantation from a fully matched unrelated donor was performed at the age of 4 months using GEFA03 protocol. Mixed donor-recipient chimerism was observed, with 60-70% chimerism in the mononucleated cell compartment and over 90% in T-lymphocyte compartment, but autologous myeloid recovery. Stable CD4+ and CD8+ T-cell counts above 200/µL were achieved after 2 months, but the patient remained transfusion-dependent. Despite satisfactory immunological reconstitution, the second transplantation due to constitutional hemolytic defect has been considered. In light of possible re-transplantation, an issue of optimal conditioning protocol with sufficient myeloid engraftment is important. For the first time Omenn syndrome is described in a compound heterozygote carrying two the novel variants p.Arg771Gly and p.Pro260* in the LIG1 gene. Patients diagnosed with SCID and Omenn syndrome showing macrocytic anemia, should be screened for DNA ligase I deficiency.

Identifiants

pubmed: 36341401
doi: 10.3389/fimmu.2022.1033338
pmc: PMC9626757
doi:

Substances chimiques

DNA Ligase ATP EC 6.5.1.1

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

1033338

Informations de copyright

Copyright © 2022 Dabrowska-Leonik, Pastorczak, Bąbol-Pokora, Bernat-Sitarz, Piątosa, Heropolitańska-Pliszka, Kacprzak, Kalwak, Gul, Burg, Ussowicz and Pac.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Mutat Res. 1983 Feb;107(2):371-86
pubmed: 6408472
Subcell Biochem. 2012;62:327-41
pubmed: 22918593
Carcinogenesis. 1983;4(5):559-64
pubmed: 6850987
J Clin Invest. 2018 Dec 3;128(12):5489-5504
pubmed: 30395541
Mutagenesis. 2020 Dec 1;35(5):391-404
pubmed: 32914844
Biol Blood Marrow Transplant. 2018 Nov;24(11):2245-2249
pubmed: 30454873
Clin Cancer Res. 2021 Jan 15;27(2):575-584
pubmed: 33082212
Nature. 2004 Nov 25;432(7016):473-8
pubmed: 15565146
Bioinformatics. 2015 Mar 1;31(5):761-3
pubmed: 25338716
Chem Rev. 2006 Feb;106(2):687-99
pubmed: 16464020
Nucleic Acids Res. 2021 Feb 22;49(3):1619-1630
pubmed: 33444456
Klin Padiatr. 2015 May;227(3):157-65
pubmed: 25985449
Lancet. 1992 Jun 20;339(8808):1508-9
pubmed: 1351188
J Clin Immunol. 2021 Jan;41(1):238-242
pubmed: 33025376

Auteurs

Nel Dabrowska-Leonik (N)

Department of Immunology, Children's Memorial Health Institute, Warsaw, Poland.

Agata Karolina Pastorczak (AK)

Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, Lodz, Poland.

Katarzyna Bąbol-Pokora (K)

Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, Lodz, Poland.

Katarzyna Bernat-Sitarz (K)

Department of Immunology, Children's Memorial Health Institute, Warsaw, Poland.

Barbara Piątosa (B)

Histocompatibility Laboratory, Children's Memorial Health Institute (IPCZD), Warsaw, Poland.

Edyta Heropolitańska-Pliszka (E)

Department of Immunology, Children's Memorial Health Institute, Warsaw, Poland.

Magdalena M Kacprzak (MM)

MedGen Medical Center, Warsaw, Poland.

Krzysztof Kalwak (K)

Department of Paediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University, Wroclaw, Poland.

Katarzyna Gul (K)

Department of Paediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University, Wroclaw, Poland.

Mirjam van der Burg (M)

Department of Pediatrics, Leiden University Medical Center (LUMC), Leiden, Netherlands.

Marek Ussowicz (M)

Department of Paediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University, Wroclaw, Poland.

Malgorzata Pac (M)

Department of Immunology, Children's Memorial Health Institute, Warsaw, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH